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 Osteoarthritis (OA) is among the top 10 diseases limiting human healthspan, and no disease 
modifying therapies currently exist. OA is a degenerative disease of the whole joint, characterized 
by articular cartilage loss, subchondral bone sclerosis, meniscal calcification, synovitis, and 
skeletal muscle dysfunction. Inhibiting the mechanistic target of rapamycin (mTOR) and 
stimulating AMP-activated protein kinase (AMPK) has extended lifespan and protected against 
post-traumatic (secondary) OA in mice. However, it remains unknown if manipulation of these 
pathways can protect against naturally occurring, age-related (primary) OA, the form most 
commonly observed in humans. The outbred Dunkin-Hartley (DH) guinea pig develops primary 
OA beginning at 5 months of age and displays high histological similarity to human OA. 
Therefore, at 5 months we sacrificed a group of DH guinea pigs to serve as young control and the 
remaining animals were randomized to receive a standard diet (age-matched controls) or diets 
enriched with rapamycin (Rap; 14ppm), metformin (Met; 1000ppm), or a combination of 
rapamycin plus metformin (Rap+Met) for 3 months. Hind limbs were collected for 
histopathological and radiographic evaluation of the knee joint. Histological OA scores in DH 
guinea pigs receiving Rap and Rap+Met were significantly lower than their age-matched controls. 
Rap treatment also reduced subchondral cortical bone thickness in the medial and lateral tibia, 
while Rap+Met reduced cortical thickness only in the lateral tibia. Both OA scores and cortical 
thickness were highly correlated with bodyweight, suggesting reduced joint loading could be 
contributing to the protective effects of Rap and Rap+Met. The minimal effect of Met may be 
attributed to low dose and indicates that Rap likely drove the protective effects of Rap+Met. 
Together, these data are the first to suggest that mTOR inhibition delays the onset of primary, age-
related OA in the DH guinea pig. 
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CHAPTER 1: INTRODUCTION 
 
Osteoarthritis (OA) is a common joint disorder affecting older adults and is among the top 
10 diseases limiting human healthspan and lifespan (Murray et al., 2013). OA is a disease of the 
whole joint, characterized by articular cartilage degeneration, thickening of subchondral bone, 
osteophyte formation, synovitis, meniscal calcification, and skeletal muscle dysfunction (R. F. 
Loeser, Goldring, Scanzello, & Goldring, 2012). Advanced age is the single greatest risk factor 
for developing OA with prevalence reaching up to 75% of adults over 70 years (Neogi & Zhang, 
2013). With no disease modifying therapies available for OA, treatment is limited to symptom 
management and eventually total joint replacement. Therefore, as the already large aged 
population continues to grow, the $140 billion annual OA-associated medical costs are expected 
to inflate (Murphy, Cisternas, Pasta, Helmick, & Yelin, 2018). 
During OA progression, chondrocytes, the only resident cell type in articular cartilage, 
undergo a hallmark homeostatic shift towards catabolism, driven by increased expression of 
proteolytic enzymes accompanied by negligible upregulation in associated inhibitors (Woessner 
& Gunja-Smith, 1991). Proteoglycan is the primary structural protein in hyaline cartilage and is 
responsible for its natural resistance to compressive load. Due to this catabolic shift, the abundance 
of proteoglycan is markedly reduced, rendering the cartilage less equipped to resist the stresses of 
joint loading (Stockwell, 1991). Underneath, in the subchondral bone, development of sclerotic 
lesions and heterogeneous stiffness distribution can expose cartilage to shear and tensile stresses, 
further increasing risk for fibrillation and failure (Burr & Gallant, 2012; E. L. Radin & Rose, 1986).  
Within the joint space, the menisci assist in facilitating the load from the femoral condyles 
to the tibial plateaus and ensuring smooth articulation. These cartilage formations are the site of 
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progressive calcium phosphate crystal deposition, which ossifies the menisci and disables their 
normal load diffusing function (Sun & Mauerhan, 2012). The degree of pathological ossification 
of the menisci closely mirrors histological OA severity in the affected compartment and clinical 
symptoms (Fuerst et al., 2009). These factors, coupled with chronic synovitis and inflammation, 
osteophyte formation, and reduction of periarticular muscle quality, lead to pain, reduced joint 
mobility, and loss of function (R. F. Loeser et al., 2012). While increased protease expression and 
some altered biomechanical factors are well characterized, the underlying signaling disruptions 
catalyzing OA pathology are not fully understood.  
OA can manifest in two forms. Post-traumatic (secondary) OA develops in response to 
injury and non-traumatic, age-related (primary) OA develops naturally over time. It has been 
estimated that primary OA accounts for as many as 91% of all cases in humans (T. D. Brown, 
Johnston, Saltzman, Marsh, & Buckwalter, 2006). However, it is difficult to predict and study the 
early onset and progression of primary OA in humans because of its idiopathic and insidious 
nature. To circumvent this issue, preclinical research typically employs injury-induced models of 
OA in mice. While this is time and cost effective, there is a growing body of evidence to suggest 
that, although primary and secondary OA share similar pathological outcomes, they are driven by 
distinct mechanisms. Only 10% of differentially upregulated and 35% of differentially 
downregulated genes are conserved between primary and secondary OA (Aki, Hashimoto, 
Ogasawara, & Itoi, 2018). There have also been several reports of genes playing inconsistent or 
opposing roles in primary and secondary OA. Deletion of Panx3, while protective against injury-
induced OA, has a detrimental effect on age-related OA pathology (Moon, Shao, Penuela, Laird, 
& Beier, 2018). While, to our knowledge, this is the most extreme dichotomy between genes 
differentially involved in primary and secondary OA, deletion of Mink1 (Yu et al., 2020), JNK1 
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and JNK2 (R. Loeser, Kelley, Harper, & Carlson, 2018), Atg5 (Bouderlique et al., 2016), Trpv4 
(O’Conor et al., 2016), and Tgfα (Usmani et al., 2016) all exert contrasting effects on primary and 
secondary OA. Together, these studies support the idea that unique mechanisms underpin primary 
and secondary OA and highlight the need to investigate therapeutic targets in both OA subtypes. 
There is an intimate link between several biological hallmarks driving both aging and the 
onset of age-related chronic disease (Kennedy et al., 2014). The mechanistic target of rapamycin 
(mTOR) and AMP-activated protein kinase (AMPK) are two energy sensing pathways similarly 
dysregulated during aging and chronic diseases such as OA (Johnson, Rabinovich, & Kaeberlin, 
2013; Pal, Endisha, Zhang, & Kapoor, 2015; Salminen & Kaarniranta, 2012; Zhou et al., 2017). 
mTOR is an evolutionarily conserved kinase which serves as a regulator of cellular metabolism 
including proliferation, protein synthesis, senescence, and survival (Loewith & Hall, 2011). 
Constitutively active mTOR during adulthood stimulates aberrant cellular proliferation at the cost 
of cell maintenance and stress resistance (Demidenko & Blagosklonny, 2008). AMPK is a highly 
conserved regulator of cellular energy homeostasis that exerts a myriad of effects thought to be 
beneficial for aging, including stimulation of autophagy (Hardie, Ross, & Hawley, 2012). 
Rapamycin bound to FKBP12 directly binds and inhibits mTOR (Sabers et al., 1995), and the 
commonly prescribed anti-diabetic drug metformin is proposed to stimulate AMPK both directly 
(Hawley, Gadalla, Olsen, & Hardie, 2002) and indirectly through mild inhibition of mitochondrial 
complex I (Owen, Doran, & Halestrap, 2000). Rapamycin extends median and maximal lifespan 
in multiple species while metformin treatment increases lifespan in some but not all studies (Jie 
Chen et al., 2017; Harrison et al., 2009; Kaeberlein et al., 2005; Martin-Montalvo et al., 2013; 
Strong et al., 2016; Vellai et al., 2003). However, extending lifespan without delaying the onset or 
slowing the progression of debilitating age-associated conditions could be viewed as detrimental. 
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Therefore, it is imperative to understand if targeting the fundamental biology of aging could be a 
successful strategy to delay the onset of naturally occurring, primary OA. 
In articular cartilage, mTOR activity increases with age in mice and activation of mTOR 
by cartilage-specific knockout of tuberous sclerosis complex 1 (TSC1), an upstream inhibitor of 
mTOR, initiates OA pathology in young, male mice (H. Zhang et al., 2017). Recent evidence 
indicates that cartilage-specific knockout (Y. Zhang et al., 2015) and pharmacological inhibition 
of mTOR (Caramés et al., 2012; Takayama et al., 2014) decreases OA pathology secondary to 
injury in young, male mice and rabbits. While these studies build support for mTOR-based 
therapeutics for the treatment of OA, the completed studies were in injury-induced models of OA. 
To our knowledge, no studies have examined the role of mTOR inhibition in delaying the onset of 
naturally occurring OA, the most common form of OA observed clinically in older adults. 
In healthy cartilage, AMPK signaling preserves chondrocyte homeostasis and extracellular 
matrix integrity by resisting inflammatory stressors (Bohensky, Leshinsky, Srinivas, & Shapiro, 
2010; Terkeltaub, Yang, Lotz, & Liu-Bryan, 2011). Loss of AMPK activity occurs with age 
(Reznick et al., 2007) and results in increased protease expression, blunted matrix anabolic 
response, and apoptosis in human chondrocytes, and contributes to more severe OA pathology in 
male mice (Petursson et al., 2013; Terkeltaub et al., 2011; Zhou et al., 2017). Metformin and other 
AMPK-activators have chondroprotective effects against inflammatory induced protease 
expression in vitro (Petursson et al., 2013; C. Wang et al., 2018) and protect against injury-induced 
OA in young male mice (Feng et al., 2020; Li et al., 2020) and rhesus monkeys (Li et al., 2020). 
In obese patients with OA, metformin use is associated with a lower rate of medial cartilage 
volume loss and decreased risk of total knee replacement (Y. Wang et al., 2019). However, the 
role of AMPK activity has not yet been investigated prospectively in primary OA.  
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While mouse models of OA are valuable for mechanistic discovery, their translation to 
humans is limited. Mice have distinct cartilage anatomy compared to humans, and injury-induced 
OA does not fully recapitulate the primary OA most commonly seen in humans (Glasson, 
Chambers, Van Den Berg, & Little, 2010). To circumvent these limitations, the Dunkin-Hartley 
(DH) guinea pig is a well-characterized outbred model of primary OA that predictably develops 
OA pathology as early as 3 months of age (A. M. Bendele & Hulman, 1988). OA disease 
progression in the DH guinea pig displays a high degree of histopathological similarity to the 
human condition (Kraus, Huebner, DeGroot, & Bendele, 2010). Articular cartilage degeneration, 
osteophytosis, subchondral sclerosis, and ossification of the menisci in the DH guinea pig are age-
related and share a similar spatial progression to humans (Huebner & Kraus, 2006; Kapadia et al., 
2000). Collectively, these characteristics support the use of the DH guinea pig to study the 
mechanisms involved in the initiation and treatment of primary OA.   
The purpose of this study was to determine if dietary rapamycin, metformin, or a 
combination of rapamycin plus metformin treatment can delay the onset or slow the progression 
of primary OA in DH guinea pigs. We hypothesized that 3 months of rapamycin, metformin and 
rapamycin+metformin started at 5 months of age would lower histological knee OA severity in 
DH guinea pigs. This study provides a unique contribution as it is the first to evaluate if lifespan 
extending treatments that slow the biological rate of aging can modify primary OA, the most 






CHAPTER 2: METHODOLOGY 
 
2.1 ANIMAL USE 
All animal procedures were approved by the Institutional Animal Care and Use Committee 
at the University of Illinois at Urbana-Champaign. Male, Dunkin-Hartley guinea pigs were 
obtained from Charles River in two cohorts of 18 and 17 animals. Animals were singly housed in 
30.8x59.4x22.9 cm clear plastic, flat bottomed cages (Thoren, Model #6) with bedding. 12 hour 
light/dark cycles were used beginning at 0600. DH Guinea pigs were allowed to acclimate for 2-3 
weeks before study measurements were collected. DH Guinea pigs were provided water and a 
standard chow diet (Evigo 2040) fortified with vitamin C (1050 ppm) and Vitamin D (1.5 IU/kg) 
ad libitum until 5 months of age. DH Guinea pigs were then either sacrificed to serve as young, 
non-OA controls (n=3), or continued the control diet (n=8), or diets enriched with encapsulated 
rapamycin (14 ppm, n=8), metformin (1000 ppm, n=8), or the combination of encapsulated 
rapamycin+metformin (14 ppm, 1000 ppm, n=8) as outlined in Figure 1. DH Guinea pigs were 
randomized to match bodyweight between groups prior to beginning treatment. Diets were 
manufactured by Envigo and enriched at concentrations previously used by the NIH Interventions 
Testing Program (Miller et al., 2014; Strong et al., 2016). Microencapsulated Rapamycin 
(Rapamycin holdings) allows increased survival of the compound during diet preparation and 
prevents digestion in the stomach (Nadon et al., 2008). Metformin was obtained from AK 
Scientific (I506). Guinea pigs began their experimental diet at ~5 months of age for 3 months. 
Food consumption was recorded on Monday, Wednesday, and Friday between 8 and 9 AM, and 
body weight was recorded before feeding on Monday. Guinea pigs provided experimental diets 
enriched with rapamycin, metformin or the combination of rapamycin + metformin were allowed 
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continued ad libitum access to food and water. Previous studies have shown that dietary Rap 
treatment, at the same dose provided in our study, significantly reduced bodyweight in male 
(Miller et al., 2011, 2014; Weiss, Fernandez, Liu, Strong, & Salmon, 2018) and female (Miller et 
al., 2011; Weiss et al., 2018) mice. Therefore, we restricted food consumption in the control group 
to match the food consumption of the experimental diet to minimize the influence of food intake 
on dependent variables.   
 
2.2 ANALYSIS OF RAPAMYCIN AND METFORMIN IN DIET AND BLOOD 
To ensure scientific rigor, samples of diets enriched with rapamycin, metformin or the 
combination of rapamycin+metformin, and aliquots of whole blood (collected as described later) 
were sent to the Bioanalytical Pharmacology Core at the San Antonio Nathan Shock Center to 
confirm drug concentrations in the diet and in circulation. Analysis was performed using tandem 
HPLC-MS as described elsewhere (Harrison et al., 2009; Tardif et al., 2015).  
 
2.3 TISSUE COLLECTION 
Following 3 months of treatment, two animals were sacrificed daily between 7 AM and 11 
AM. Food and water were removed from the cages 2-4 hours before euthanasia. Animals were 
anesthetized in a chamber containing 5% isoflurane gas in oxygen and maintained using a gas 
mask with 1.5-3% isoflurane. Once reflexively unresponsive, the thoracic cavity was opened for 
blood collection by cardiac venipuncture and subsequent excision of the heart. After death, the 
right hind limb was removed at the coxofemoral joint and fixed in 10% neutral buffered formalin 
for 48 hours, then transferred to 70% ethanol for storage until processed for histology. The soleus 
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muscle was also collected from the left hind limb, snap frozen in liquid nitrogen, and stored at -
80C for further analysis.  
 
2.4 HISTOLOGY 
Knee joints were decalcified in a 5% EDTA solution, changed every 2-3 days, for 6 weeks. 
Joints were then cut in a coronal plane along the axis of the medial collateral ligament as described 
(Kraus et al., 2010). The transected joint was embedded in paraffin and sectioned at 5 micrometer 
increments, stained with Toluidine Blue as recommended by the Osteoarthritis Research Society 
International (OARSI) guidelines (Kraus et al., 2010). Slides were scanned using the Hamamatsu 
NanoZoomer Digital Pathology System, providing 460 nm resolution. Scan focus points were set 
manually along the articular cartilage. Imaged slides were then scored in a blinded fashion for OA 
severity as described by the OARSI Modified Mankin guidelines (Kraus et al., 2010).  
 
2.5 ISOLATION AND CULTURE OF PRIMARY PORCINE CHONDROCYTES 
 Healthy cartilage was scraped from porcine metacarpophalangeal joints and chondrocytes 
were isolated by enzymatic digestion using pronase (Sigma, 11459643001) and type II collagenase 
(Worthington Medical, LS004176). Chondrocytes were then seeded at a density of 5x105 cells/well 
in 6-well plates and resuspended in Dulbecco’s modified Eagle’s medium (DMEM) containing 4.5 
g/L glucose, HEPES buffer, and L-glutamine (Fisher, 12430062). Media was supplemented with 
5% fetal bovine serum (FBS), 100x non-essential amino acids, and antibiotics (100 U/mL 
penicillin and 0.1 mg/mL streptomycin). Cells were cultured for  4 days at 37°C and 5% CO2 until 
confluency was reached at which point they were treated with rapamycin at 0.5, 1, 1.5, 2, or 3 nM 
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for 48 hours. Cells were then washed once in PBS without Ca2+ or Mg2+ before being collected in 
250 uL of RIPA buffer and flash frozen in liquid N2.  
 
2.6 TISSUE HOMOGENIZATION AND WESTERN BLOT ANALYSIS 
 Cells were lysed and homogenized by sonication, and soleus muscles were pulverized 
using a liquid nitrogen-cooled mortar and pestle. 50 mg of soleus homogenate was then suspended 
in 1mL of RIPA buffer with freshly added Halt™ protease and phosphatase inhibitor cocktail 
(ThermoFisher, 78430) and 60 mg of zirconium oxide beads. Supernatant was collected following 
two 3-minute cycles in a Bullet Blender bead homogenizer (Next Advance) and 
microcentrifugation at 800g. Samples were diluted to equal concentrations following a 
bicinchoninic acid (BCA) assay (ThermoFisher, 23225) to determine total protein concentration. 
Protein denaturation was achieved using Laemmli Sample Buffer (Bio-Rad, 1610737) with 2-
mercaptoethanol (Bio-Rad, 1610710) and heating for 5 minutes at 95°C. 
Twenty micrograms of protein were loaded per lane for sodium-dodecyl-sulfate 
polyacrylamide-gel-electrophoresis (SDS-PAGE) using a 4-15% Mini PROTEAN gradient gel 
(Bio-Rad, 4561083). Protein was transferred to polyvinylidene fluoride (PVDF) membranes and 
blocked for 1 hour at room temperature using 5% bovine serum albumin (BSA) in Tris-buffered 
saline with 0.1% Tween-20 (TBST). Membranes were then incubated with rabbit monoclonal 
antibodies raised against ribosomal protein S6 (rpS6; 1:1,000 in 5% BSA/TBST; Cell Signaling 
2217) and rpS6 phosphorylated at Ser235/236 (p-rpS6; 1:2,000 in 5% BSA/TBST; Cell Signaling, 
4858) overnight at 4°C. After three 5-minute TBST washes, membranes were incubated with a 
horseradish peroxidase (HRP)-linked anti-rabbit IgG (1:10,000 in 5% BSA/TBST; Cell Signaling 
7074) for 1 hour at room temperature. Membranes the underwent three 5-minute TBST washes 
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followed by an incubation in SuperSignal West Dura Extended Duration Substrate (ThermoFisher 
34076) and were imaged using a ChemiDoc XRS+System (Bio-Rad 1708265). Protein bands were 
quantified by densitometry using the Quantity One imaging program and were expressed as a ratio 
of phosphorylated- to total rpS6.  
 
2.7 MICRO COMPUTED TOMOGRAPHY (µCT) 
Right hind limbs were scanned using a Rigaku CT Lab GX130 at 120 uA and 110 kV for 
14 minutes, achieving a pixel size of 49 um. Half of the guinea pigs (n=4 per group) were scanned. 
All scans were segmented using identical thresholds to allow comparison between animals. Scans 
were first processed in Amira 6.7 (ThermoFisher) to create 3D joint reconstructions. Ossified 
meniscus volume was quantified using material statistics after segmenting menisci to a separate 
material. The thickness mapping function was visualized using a temperature-based volume 
rendering to illustrate spatial thickness distribution across the subchondral plates. A series of 
dilation, erosion, filling, and image subtraction functions were then used to isolate trabecular and 
cortical bone similar to the method described (Buie, Campbell, Klinck, MacNeil, & Boyd, 2007). 
Scans were resliced 4 times along axes perpendicular to medial and lateral tibial and femoral 
articular surfaces and binarized.  
NIH ImageJ software and BoneJ plugin were used to quantify thickness, spacing, and 
volume fraction measurements (Doube et al., 2010; Schneider, Rasband, & Eliceiri, 2012). 
Regions of interest (ROI) were placed along the articular surfaces of the tibial plateaus and femoral 
condyles to measure subchondral cortical thickness. ROIs were placed in the trabecular bone of 
the medial and lateral tibia and femur where trabecular thickness, spacing, and bone volume 
fraction were measured.  
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2.8 STATISTICAL ANALYSIS 
 A two-way repeated measures ANOVA (time x treatment) was performed to determine 
differences in food consumption and body weight. Upon a significant interaction, a Holm-Sidak 
multiple comparisons test was used. For all other variables, differences were detected using one-
way ANOVA with Fisher’s Least Significant Difference test comparing treatment groups to 8 
month controls. Pearson’s R was used to determine correlation between variables. Statistical 


















CHAPTER 3: RESULTS 
 
3.1 INFLUENCE OF RAPAMYCIN, METFORMIN, AND RAPAMYCIN+METFORMIN ON 
FOOD CONSUMPTION AND BODYWEIGHT  
Male DH guinea pigs were provided standard chow or standard chow enriched with 
rapamycin (Rap), metformin (Met), or rapamycin plus metformin (Rap+Met) for 12 weeks (Figure 
2A). The average daily intake of Rap and Met in each diet group is reported in Table 1. There was 
a main effect for time that was driven by decreased food consumption in the early weeks in DH 
guinea pigs treated with Rap (Weeks 1 and 2; p<0.05), Met (Week 3; p<0.05), and Rap+Met (week 
1; p<0.05). Food consumption did not differ from week 0 the remainder of the study. There were 
no significant differences between treatments.  
Despite largely matching food intake over the 12-week intervention, there was a significant 
effect of time, treatment and interaction (time by treatment) in body weight. Rap+Met and Rap 
treated DH guinea pigs were smaller (p<0.05) than control starting at week 3 and week 4, 
respectively, until the end of the study (Figure 2B). There were no differences in body weight 
between DH guinea pigs treated with Met versus control. 
 
3.2 IMPACT OF RAPAMYCIN, METFORMIN, AND RAPAMYCIN+METFORMIN ON 
GLUCOSE AND LACTATE METABOLISM 
At sacrifice, Rap and Rap+Met treated DH guinea pigs displayed increased blood glucose 
concentrations compared to control (p<0.05; Figure 2C). Lactate concentrations were increased in 
the Rap+Met group (p<0.05; Figure 2D). Treatment with Met alone exerted no apparent effects on 
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blood glucose or lactate compared to control. Analysis of blood revealed that the experimental 
diets were sufficient to increase circulating levels of Rap and Met (Figures 2E-F). 
 
3.3 RAPAMYCIN  INHIBITED mTOR IN SKELETAL MUSCLE AND PRIMARY PROCINE 
CHONDROCYTES 
Activation of the Ser/Thr kinase mTOR results in a phosphorylation cascade through p70 
S6 kinase 1 and its substrate ribosomal protein S6 (rpS6). Therefore, phosphorylation status of 
rpS6 is commonly used as a surrogate measurement for mTOR activity. To show that Rap is 
capable of inhibiting mTOR in chondrocytes, the resident cell type in articular cartilage, we 
cultured primary porcine chondrocytes in media enriched with increasing concentrations of Rap. 
Phosphorylation of rpS6 was reduced by Rap in a dose-dependent manner, with complete loss of 
rpS6 phosphorylation at 3 nM (Figure 3A). Western blot analysis of skeletal muscle lysate from 
the soleus of DH guinea pigs revealed that treatment with Rap and Rap+Met significantly reduced 
phosphorylation of rpS6 at residues Ser235/236 (Figures 3B-C).  
 
3.4 RAPAMYCIN AND RAPAMYCIN PLUS METFORMIN TREATMENT ATTENUATED 
THE AGE-RELATED PROGRESSION OF PRIMARY OA IN THE MEDIAL TIBIA 
Control animals were sacrificed at 5 and 8 months, which is consistent with the age-related 
progression of mild to moderate OA in DH guinea pigs. As expected, average OARSI scores 
(Figure 4B) significantly increased from 5 to 8 months (p<0.05), driven by loss of normal 
chondrocyte cellularity (p<0.05; Figure 4C), proteoglycan content (p<0.05; Figure 4D), and a non-
significant increase in articular cartilage structural damage (ACS; p=0.11; Figure 4E). Rap and 
Rap+Met treatment prevented the progression of age-related OA from 5 to 8 months, as evident 
by lower total OARSI scores compared to 8-month controls (p<0.01; Figure 4E). The protective 
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effects of Rap were driven primarily by maintained proteoglycan content (p<0.001; Figure 4D). 
There were also trends for Rap to decrease in cellularity disruption (p=0.05; Figure 4C) and ACS 
(p=0.05; Figure 4E). Rap+Met prevented the loss of normal cellularity (p<0.05; Figure 4C) and 
proteoglycan content (p<0.001; Figure 4D), and ACS (p=0.05; Figure 4E). While Met did not 
decrease the total OA score (Figure 4B), it did maintain proteoglycan content (p<0.05; Figure 4D).  
 
3.5 DECREASED SUBCHONDRAL AND DIAPHYSEAL CORTICAL BONE THICKNESS IN 
RAPAMYCIN TREATED ANIMALS 
Mean subchondral cortical thickness was significantly decreased by Rap in the medial 
(p<0.05; Figure 5A) and lateral (p<0.05; Figure 5B) tibial plateaus, and non-significantly in the 
medial femoral condyle (p=0.06; Figure 4C). Rap+Met decreased cortical thickness only in the 
lateral tibia (p<0.05; Figure 5B). Met treatment alone exerted no apparent effects on subchondral 
bone. Further investigation revealed that cortical thickness at the femoral diaphysis was also 
decreased by Rap (p<0.001; Figure 5D) and Rap+Met (p<0.05; Figure 5D), and this change was 
proportionate to the decrease in cortical thickness in articular bone (Figure 5E). Femoral 
epicondylar width (Figure 5F) was not different between groups, suggesting that our treatments 
did not affect skeletal development or overall bone architecture.  
 
3.6 BODYWEIGHT CORRELATED WITH REDUCTIONS IN OARSI SCORES AND 
SUBCHONDRAL THICKNESS 
OA scores (R2=0.685, p=0.0001; Figure 5A) and medial tibial subchondral thickness 
(R2=0.55, p=0.001; Figure 5B) displayed a significant positive correlation to bodyweight These 
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data suggest that decreases in OARSI scores and subchondral cortical thickness were associated 























CHAPTER 4: DISCUSSION 
 
The purpose of this study was to test if dietary Rap (14ppm), Met (1000ppm) or Rap+Met 
treatment at concentrations previously shown to extend lifespan can delay the onset of age-related 
OA in the outbred DH guinea pig. Dietary Rap and Rap+Met treatment prevented the age-related 
progression of OA severity from 5 to 8 months as evident by lower OARSI scores in articular 
cartilage from the medial tibial plateau. Rap and Rap+Met also reduced subchondral bone 
thickness in multiple joint compartments. Changes in OA score and subchondral thickness were 
correlated with bodyweight, suggesting the protective effects of Rap and Rap+Met may be 
associated with lower joint loading. Met alone demonstrated little effect on primary OA pathology 
in articular cartilage or subchondral bone. While Rap and Rap+Met treatment were beneficial for 
articular cartilage, we did observe off-target effects such as elevated blood glucose and lactate 
concentrations. Although the mTOR pathway has been investigated in injury-induced models of 
OA, this is the first study to indicate that mTOR could be a therapeutic target for age-related, 
primary OA. 
Articular cartilage is the hallmark tissue involved in OA pathology and has traditionally 
been the primary focus of OA research. In our study, Rap and Rap+Met treatment lowered OA 
scores in the medial tibia of 8-month DH guinea pigs.  The dose of Rap consumed in the diet was 
0.72±0.06 mg/kg/day and 0.68±0.09 mg/kg/day in the Rap and Rap+Met groups, respectively. 
This dietary dose of Rap is similar to doses that are protective against secondary OA administered 
systemically by intra-peritoneal injection (Caramés et al., 2012; 1 mg/kg/day) and locally by intra-
articular injection (Takayama et al., 2014; 0.914 mg/kg/day). Additionally, the effect of Rap and 
Rap+Met on OA pathology in the DH guinea pig resembles the robust protection against secondary 
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OA in mice by genetic ablation of mTOR (Y. Zhang et al., 2015). This suggests that the protective 
effects of Rap against OA pathology are driven primarily by its actions within articular cartilage 
and not off-target effects on other tissues. Additionally, at doses sufficient to extend lifespan and 
protect against post-traumatic OA in mice, Rap and Rap+Met were shown for the first time to 
delay the onset of primary, age-related OA pathology in the DH guinea pig.  
We also demonstrated that Rap inhibited mTOR in cultured chondrocytes derived from 
porcine articular cartilage as well as periarticular skeletal muscle in DH guinea pigs, congruent 
with the effect of Rap on multiple tissues and cell types (N. F. Brown, Stefanovic-Racic, Sipula, 
& Perdomo, 2007; Caramés et al., 2012; Houde et al., 2010; Philp et al., 2015; Roh, Han, Tzatsos, 
& Kandror, 2003; Sasaki et al., 2012; C. A. Wolff et al., 2020). In addition to maintaining articular 
cartilage score and proteoglycan content, Rap+Met maintained normal chondrocyte cellularity in 
the medial tibial plateau. An increase in cellularity and chondrocyte clustering near articular 
cartilage damage and fibrillations is thought to be indicative of chondrocyte proliferation and a 
failed attempt to repair cartilage damage (Rothwell & Bentley, 1973). Activation of mTOR has 
been shown to initiate the onset of structural OA pathology by stimulating chondrocyte 
proliferation, and inhibition of cellular proliferation by Rap protected against secondary-OA (H. 
Zhang et al., 2017). Our unpublished data in cultured chondrocytes suggest that mTOR inhibition 
by Rap and Rap+Met shifts the allocation of proteostatic resources from cell proliferation to cell 
maintenance by inhibiting chondrocyte proliferation and maintaining protein synthesis. These 
findings in culture are consistent with the decrease in cellularity, proteoglycan loss and articular 
damage in vivo in the DH guinea pigs and likely suggest that Rap and Rap+Met lower OA 
pathology by restoring proteostatic mechanisms. However, this supposition requires additional 
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studies to understand how mTOR inhibition effects proteostasis to delay the onset of OA pathology 
in vivo.  
OA progression is characterized by subchondral bone sclerosis, which correlates with  
articular cartilage loss in humans (Crema et al., 2014) and precedes cartilage damage in some 
animal models of OA including the DH guinea pig (Burr & Gallant, 2012; Carlson, Loeser, Purser, 
Gardin, & Jerome, 2009; Huebner, Hanes, Beekman, TeKoppele, & Kraus, 2002; T. Wang, Wen, 
Yan, Lu, & Chiu, 2013). uCT analysis revealed that treatment with Rap decreased subchondral 
cortical thickness in the medial and lateral tibia, and Rap+Met decreased thickness in the lateral 
tibia. Initially, this may be viewed as resistance to sclerotic lesions. Femoral epicondylar width, a 
joint dimension previously used to assess treatment effects on longitudinal bone growth (Hamrick, 
Ding, Ponnala, Ferrari, & Isales, 2008), was unchanged between groups. This suggests that Rap 
treatment prevented subchondral bone sclerosis without influencing the structural development of 
bone. However, further investigation revealed that changes in subchondral bone thickness were 
not site-specific and were also observed proportionately at the femoral diaphysis. DH guinea pigs 
have been reported to reach skeletal maturity between 4 months (Radakovich, Marolf, Culver, & 
Santangelo, 2019) and 7 months (Kraus et al., 2010; Zuck, 1938). Since Rap and/or Met treatment 
started at 5 months of age, it is possible that treatment began before skeletal maturity was reached. 
In support of this idea, DH guinea pigs continue gaining weight until at least 18 months of age 
(Alison M. Bendele & Hulman, 1991) and during this time there is an increase in tibial and femoral 
cortical thickness (Radakovich et al., 2018). Therefore, administration of Rap may have halted the 
rate of bone remodeling and prevented increases in cortical thickness seen in response to normal 
growth.  
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 The effects of Rap and Rap+Met on cortical thickness are likely due to the effect of mTOR 
inhibition on skeletal remodeling and development (Jianquan Chen & Long, 2018). Bone 
remodeling is a dynamic process mediated by osteoblasts and osteoclasts, the cell types responsible 
for synthesizing and resorbing mineralized bone matrix, respectively. Deletion of the mTOR 
inhibitor tuberous sclerosis complex 1 (TSC1) in bone marrow mesenchymal stem cells (osteoblast 
precursors) results in thickened diaphyses due to increased peri- and endosteal bone matrix 
synthesis (Wu et al., 2017). Similarly, 40-60% of humans with an autosomal dominant genetic 
disease causing loss of function mutations in TSC1 or TSC2 display sclerotic bone lesions (Fang 
et al., 2015). Deletion of TSC1 can induce similar phenotypes in mice, and treatment with Rap 
completely prevents the development of sclerotic lesions (Fang et al., 2015). Further, Rap 
treatment in young, skeletally immature rats decreased endochondral bone growth resulting in 
shorter diaphyses (Sanchez & He, 2009). Interestingly, Rap treatment increases osteoclastogenesis 
(Y. Zhang et al., 2017), while also increasing apoptosis and decreasing enzymatic activity in 
osteoclasts (Glantschnig, Fisher, Wesolowski, Rodan, & Reszka, 2003). These somewhat 
opposing responses in osteoclasts may act as a mechanism to protect against bone loss, as mTOR 
inhibition also decreases osteoblast differentiation and new bone matrix synthesis (Xian et al., 
2012). If osteoclasts were able to develop unrestrained while osteoblast differentiation was 
blunted, there would be a stark loss of bone mass. Agreeing with this idea, rats treated with the 
mTOR-inhibitor everolimus displayed resistance to ovariectomy-induced bone loss (Kneissel et 
al., 2004) and Rap treatment attenuated age-related alveolar bone loss in mice (An et al., 2017). 
Additionally, our findings show that a lower body weight with Rap and Rap+Met treatment 
is correlated to lower OA pathology and subchondral and diaphyseal bone thickness. This is in line 
with Wolff’s law which states that bone will adapt to the forces to which it is subjected (J. Wolff, 
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1892). Therefore, the Rap-mediated decrease in bodyweight reduced loading forces within the 
joint space and along diaphysis, thus decreasing the stimulus for new bone matrix formation and 
reducing mechanical stress on the articular cartilage (Eric L Radin et al., 1984). Previous studies 
have demonstrated that lower bodyweight in calorie restricted animals results in lower OA 
pathology and femoral cortical thickness (Alison M. Bendele & Hulman, 1991; Hamrick et al., 
2008; Radakovich et al., 2019). There is also precedent in the literature that dietary Rap (14ppm) 
treated male and female mice have lower bodyweight than control animals (Miller et al., 2011; 
Weiss et al., 2018). Therefore, to minimize the influence of dietary intake on treatment outcomes, 
we prorated food intake of the age-matched control animals to match the consumption of Rap and 
Rap+Met-treated animals. If caloric restriction were entirely responsible for the protective effects 
of Rap and Rap+Met, the same protection would have been observed in the control group. Caloric 
restriction in previous studies and Rap and Rap+Met treatment in the current study induce similar 
body weights in DH guinea pigs which indicates that smaller size may have partially contributed 
to the protective effects of Rap and Rap+Met. (Alison M. Bendele & Hulman, 1991; Hamrick et 
al., 2008; Radakovich et al., 2019). However, despite similar body weights after CR and Rap 
treatment in DH guinea pigs, the degree to which Rap and Rap+Met lowered OA scores in our 
study was greater than that of caloric restriction. While we cannot directly compare these two 
different studies, these findings may suggest that Rap and Rap+Met were exerting additional 
effects than weight restriction alone.  
 Although Rap and Rap+Met treatment were protective against primary OA and decreased 
subchondral cortical thickness, Met alone largely had no impact on OA pathology apart from 
preserving proteoglycan content. This differs from several studies in which Met has exerted 
chondroprotective effects in vitro (Petursson et al., 2013; C. Wang et al., 2018) or protected against 
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secondary OA in mice (Feng et al., 2020; Li et al., 2020) and rhesus monkeys (Li et al., 2020). In 
these studies, Met similarly prevented proteoglycan loss but also exerted additional effects to those 
observed in our study and was sufficient to decrease total OA score. Our study is unique in that 
we employed a primary model of OA. Our results could indicate that Met is one of the dichotomous 
treatments exerting differential effects on primary and secondary OA progression. However, 
retrospective analysis in humans showing diabetic patients receiving Met display decreased 
cartilage volume loss and lower incidence of knee replacement (Y. Wang et al., 2019) point to an 
alternative cause, most likely insufficient dose.  
In our study, diet enriched with Met (1000ppm) resulted in an average consumption of 
39.9±1.7 mg/kg/day and 44.5±5.7 mg/kg/day in DH guinea pigs treated with Met and Rap+Met, 
respectively. Assuming an average bodyweight of 70 kg, the highest approved Met dose for 
treatment of Type 2 Diabetes Mellitus in humans is 35 mg/kg/day (He & Wondisford, 2015), which 
is much lower than the doses at which Met has been shown to be protective against secondary OA 
by Feng et al. (2020; 200 mg/kg/day) and Li et al. (2020; 100, 200 mg/kg/day). However, the 
fractional bioavailability (F) of Met in circulation following oral consumption in rats (F=30%; 
Choi, Sang, & Lee, 2006) is lower than humans (F=55%; Graham et al., 2011), making a 100-300 
mg/kg/day dose in rats clinically relevant. Therefore, the diet in our study may have provided a 
dose that is 6-7 fold lower than commonly observed in similarly sized rodents and humans. In 
support of this notion, Met concentrations ~2-3 hours after removing food from the cage were 277 
ng/mL, which is 5-7-fold lower than the 1300-2000 ng/mL observed in healthy and diabetic 
humans following a normal therapeutic dose (Graham et al., 2011). Met is typically provided as a 
bolus 1-2 times per day and may also contribute to why the circulating concentration of Met would 
be lower in the current study where Met was provided ab libitum in the diet throughout the day. 
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Interestingly, the same dose that extended median lifespan and some indices of healthspan in the 
genetically homogenous C57BL/6 mice (Martin-Montalvo et al., 2013) showed no significant 
effect in genetically heterogenous UM-HET3 mice (Strong et al., 2016). Outbred animals like DH 
guinea pigs and UM-HET3 mice more closely recapitulate the diverse human population seen 
today. Therefore, if the dose of Met that benefits inbred animals is insufficient to benefit 
genetically heterogeneous animals, this may bring into question if Met can be translated to clinical 
populations as an anti-aging compound.  
Despite providing novel findings, our study had some limitations and adverse effects. First, 
we have not yet directly measured mTOR activity in articular cartilage of DH guinea pigs. We 
anticipate completing immunohistochemical (IHC) analysis of articular cartilage to provide a more 
insight into mTOR activity, downstream targets, and the contribution to primary OA pathology. 
However, our data collectively show that Rap is able to inhibit mTOR in DH guinea pigs in 
periarticular muscle and in cultured chondrocytes. Rap or Rap+Met treatment in DH guinea pigs  
elevated blood glucose levels compared to controls. Hyperglycemia and impaired glucose 
tolerance are well documented side effects of Rap treatment (Miller et al., 2014; Weiss et al., 
2018). The addition of Met to Rap treatment prevented the Rap-induced glucose intolerance in 
female but not male mice (Weiss et al., 2018). Similarly, Met treatment in the current study did 
not elicit a glucoregulatory protective effect in Rap treated male DH guinea pigs. We cannot 
specifically state that this was due to sex differences since we have not yet tested Rap and Rap+Met 
in female DH Guinea pigs and as stated previously the Met dose may have been too low. Treatment 
with Rap+Met also increased blood lactate concentrations compared to controls. Our unpublished 
data indicate that Rap and Rap+Met decreased maximal skeletal muscle oxidative capacity which 
may cause a compensatory increase in glycolytic flux and lactate production. To avoid the side 
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effects of systemic administration, treatment could have been injected intra-articularly to localize 
the effects of treatments to the joint space. However, Rap and Rap+Met are known for their ability 
to extend lifespan when consumed systemically. Therefore, administration via intra-articular 
injection would limit pleiotropic effects on tissues outside the joint space and likely unfasten the 
lifespan-extending properties of these compounds from their protective effects against OA 
pathology.   
Our findings suggest that inhibition of the mTOR pathway is protective against primary 
OA pathology. Although our study was a necessary first step, we will next identify the mechanisms 
by which mTOR attenuation modifies primary, age-related OA. We acknowledge that a set of 
proximal mechanisms unique to primary and secondary OA initiate a cascade of homeostatic 
disturbances and may eventually converge on mutual pathways, such as mTOR, to elicit the same 
pathological hallmarks. However, the mechanisms downstream of mTOR may also differ, in which 
case mTOR is simply an overlapping node in two networks of dysregulation in pathways otherwise 
exclusive to primary and secondary OA. We are also interested in exploring different dosing 
intermittent dosing schemes or rapalogs with more specificity to inhibit mTOR and avoid 
unwanted side effects. Due to our likely insufficient dose of Met, further work is also needed to 
determine the utility of Met as a therapeutic agent against primary OA. Martin-Montalvo et al. 
(2013) showed that Met at the concentration provided in our study (1000 ppm) was sufficient to 
increase average lifespan in C57BL/6 mice, but became toxic and decreased lifespan at a dose 10-
fold higher. Because of the mentioned differences in Met pharmacodynamics between rats and 
humans, it may be prudent to investigate the effects of Met on primary OA pathology using a dose 
in-between the extremes used by Martin-Montalvo et al. (2013).  
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CHAPTER 5: CONCLUSION 
 
Extension of lifespan without a proportionate extension of healthspan could be considered 
detrimental. In our study, we show for the first time that the mTOR inhibitor Rap, alone or in 
combination with Met, can prevent the progression of age-related OA, the form of OA most 
commonly seen in aging humans. Rap and/or Rap+Met maintained articular cartilage structure, 
proteoglycan content and chondrocyte cellularity which culminated into lowering the total OA 
scores in the articular cartilage of the medial tibia. Met treatment alone preserved proteoglycan 
content but was not sufficient to lower the total OA score. In bone, Rap and Rap+Met decreased 
both subchondral and diaphyseal cortical thickness, suggesting that mTOR inhibition mediated a 
reduction in global cortical thickness rather than a site-specific resistance to subchondral sclerosis. 
These decreases in cortical thickness and cartilage OA scores were highly correlated to 
bodyweight, as is common in the DH guinea pig. However, Rap and Rap+Met seem to exert further 
benefits in articular cartilage compared to other studies in which caloric restriction reduced 
bodyweight and OA severity. Therefore, Rap delays the onset of OA by more than decreasing 
bodyweight alone. Met exerted no apparent effects on cortical bone and minimally affected 
articular cartilage, which was likely due to an insufficient dose and will require further 
investigation. Our findings reveal the pathological contribution of mTOR in primary OA and our 
future research aims to explore the down- and upstream mechanisms by which mTOR inhibition 





CHAPTER 6: TABLE AND FIGURES 
 
  Experimental Diet 




(14 ppm, 1000 ppm) 
Rapamycin mg/day 
0.61±0.07 - 0.54±0.06 
mg/kg/day 0.72±0.06 - 0.68±0.09 
Metformin mg/day 
- 38.2±2.0 35.5±3.9 
mg/kg/day - 39.9±1.7 44.5±5.7 
 
Table 1. Average daily intake of Rap and Met for DH guinea pigs receiving experimental diets. All data are presented 
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Figure 2: Effects of rapamycin, metformin and rapamycin+metformin in bodyweight, glucose and lactate 
metabolism, and circulating rapamycin and metformin. Average weekly (A) food consumption and (B) body 
weight of DH guinea pigs beginning 2 weeks prior to randomization and through the 12-weeks of treatment. Blood 












Figure 3: Rapamycin inhibits mTOR in articular chondrocytes and skeletal muscle.   
A) Representative western blot images of phosphorylated- and total rpS6 from chondrocytes cultured in 
increasing concentrations of rapamycin for 48 hours (0 to 3nM) and (B) skeletal muscle of DH guinea pigs. C) 
Quantification of the ratio of phosphorylated to total rpS6. All data are expressed relative to 8 month controls. 










































Figure 4: Rapamycin and rapamycin+metformin decreased OA pathology in medial tibial cartilage.  
A) Toluidine blue staining of knee joint sections from 5-month control, 8-month control, and rapamycin, metformin, 
and rapamycin+metformin-treated DH guinea pigs. Rapamycin and rapamycin+metformin treatment resulted in lower 
total OARSI scores (B). Individual OARSI criteria including chondrocyte cellularity (C), proteoglycan content (D), 
and articular cartilage structure (ACS; E) are also shown. (*p<0.05 compared to 8 mo. controls; **p<0.01 compared 




Figure 5: Rapamycin and rapamycin+metformin reduced articular cortical thickness. 
Subchondral cortical thickness measured in the medial tibia (A), lateral tibia (B) medial femur (C), and femoral 
diaphysis (D). The ratio of articular to diaphyseal thickness (E) and femoral epicondylar width (F) were not different 





















































































































Figure 6: OA score and subchondral cortical thickness were correlated to bodyweight.  
OA score (A; R2=0.685, p=0.0001) and subchondral cortical thickness (B; R2=0.551, p=0.001) displayed a significant 
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